PARP inhibitors have demonstrated synthetic lethality in cells with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations and in cells with homologous recombination deficiency (HRD).2, 3, 4. Here, PARP1 is linked to breast carcinoma.